Scribe Therapeutics
PublicScribe Therapeutics is now publicly traded
The data on this page reflects Scribe Therapeutics's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Last Round
Grant
Jun 18, 2026
Total Funding Raised
$175M
Company Overview
Scribe Therapeutics operates in Biotech and is based in Alameda, California. It has raised $175M.
Scribe Therapeutics is a biotechnology company that develops engineered CRISPR technologies and genetic medicines aimed at treating genetic diseases.
Sector
Biotech
AI Layer
Infrastructure
Scribe Therapeutics Comparables
Compare Scribe Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Arbor Biotechnologies | 86% | |
| YolTech Therapeutics | 83% | |
| Epicrispr Biotechnologies | 82% |
For institutional investors. Book with your work email.
Scribe Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jun 18, 2026 | ||||
| Convertible Debt | May 16, 2023 | ||||
| Series B | Mar 31, 2021 | ||||
| Series A | Oct 6, 2020 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Scribe Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B, Series A |
| RA Capital Management | Series B |
| Perceptive Advisors | Series B |
| Avoro Ventures | Series B |
| Avoro Capital | Series B |
| OrbiMed | Series B |
| T. Rowe Price | Series B |
For institutional investors. Book with your work email.
Scribe Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.